Encorafenib,Cetuximab,Binimetinib
Pfizer,Eli Lilly,Array Biopharma
['beacon']
#esmo22
genomic mechanisms of resistance to #brarv600e by from #beacon braf is detected by ctdna in 93% baseline acquired kras, nras, map2k + met #mutations most acquired #mutations were subclonal and multiple were present #translationalresearch 
Medical Oncologist MD, BSc Vall d'Hebrón @vallhebron @VHIO

Vicepresident Secció Metges MIR del COMB @COMBarcelona 

Asesor @SalutUIC

#oncology #research #MIR